NewsRoom Articles - Page 216 of 221

MondayJul 13, 2020 3:00 pm

Managing Clinical Trials Digitally

Digital data collection has played major roles in several aspects of our lives, reduced waste and removed room for human error. For example, airlines today transfer most of the data collection function to their customers, and we are willing (and even happy) to use our mobile devices to provide all the needed data, such as our seat preferences and other personal details. Banks have done the same, and so have other service providers. However, the field of clinical research has been slow in waking up to the immense benefits of digital data collection, and we cover some of the major…

MondayJul 13, 2020 10:00 am

What is the Difference Between SaaS and Hosted EHR Solutions?

Are you a facility owner considering the different options available in the Electronic Health Record System space? If that’s the case, you have probably heard or seen the term “SaaS" and “Hosted” to refer to different ways of licensing EHR products. These terms are always used interchangeably, and that should not be the case. If you have heard these terms from your vendors, then you need to understand the difference. What is SaaS? SaaS is defined as software as a service. It is a way to deliver software to end-users who do not want the task of maintaining and running…

FridayJul 10, 2020 3:00 pm

Tips on Meeting FDA Device Design Requirements

Are you a device manufacturer in the medical industry? Then you may be thinking that the FDA design controls are confusing terms on your process. These regulatory design requirements shouldn’t be shrouded in confusion, and we share some tips below that will help you enjoy being a biomedical product designer who meets or even surpasses the FDA regulatory requirements. It Would Be Best If You Didn’t Believe in Misconceptions A heavy load of documentation has been the biggest misconception about meeting the FDA design controls. If you have volumes of documentation on how to meet FDA design requirements, then your…

FridayJul 10, 2020 2:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2020 Financial, Business Report; Revenues Up, Margins Stay Strong

POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back” Company closed transaction resulting in gross cash proceeds of approximately $2.2 million Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Q1 2020 financial results and business highlights (http://ibn.fm/mFwpq) as well as receipt of cash proceeds of $2.2 million from exercise of warrants (http://ibn.fm/2n6x5). “[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held…

FridayJul 10, 2020 10:00 am

Microsurgery Robot Market Expected to Grow Exponentially

The use of robotics in surgery is seeing double-digit growth and this trend is expected to continue for years to come. We look at some of the forces that are behind the anticipated exponential growth in the microsurgery robot market. Growing Awareness of the Benefits of Robotic Microsurgery Microsurgery by the use of robots confers a lot of benefits over the traditional surgical modalities. These benefits include shorter hospital stays (since patients heal faster when compared to the longer durations required for traditional incisions to heal), a drastic drop in the incidence of post-surgical complications (partly because the microsurgery procedure…

ThursdayJul 09, 2020 3:00 pm

4 Notable Factors Behind the Explosion in Self-Injection Device Space

According to forecasts, the demand within the self-injection devices market is anticipated to grow a great deal in the years to come. This increase can be attributed to a number of factors as the discussion below explores. Transferring Responsibility to Individuals Over the years, there has been a growing consensus among experts and researchers that individuals (patients) need to play a bigger role in managing the different health conditions that they are afflicted with. In this regard, innovation efforts have gone towards developing a variety of products that put patients in the driver’s seat, and those products include self-injection devices.…

ThursdayJul 09, 2020 10:00 am

EU Grants Orphan Medicine Status to Liver Cancer Drug

The European Medicines Agency (“EMA”) recently granted Orphan Medicinal Product designation in the EU to MIV-818 used for the treatment of patients with hepatocellular carcinoma (“HCC”), the primary type of liver cancer. This designation was granted after thorough and careful medical research and guidance about the drug. Orphan Medicinal Product designation gives specific regulatory and financial bonuses to firms to help in developing and marketing therapies that treat chronically debilitating conditions or life-threatening diseases. Studies show that five people in a population of 10,000 individuals are suffering from HCC, a fatal ailment in the European Union. The designation has been…

WednesdayJul 08, 2020 2:00 pm

Spike in Neurological Diseases Fuels Market for Cerebrospinal Fluid Management Products

The world market for cerebrospinal fluid management products is witnessing tremendous growth with rising levels of competition, according to the forecasting done by Transparency Market Research. The major stakeholders in the global market are putting more emphasis on the development of a new product, with further predictions to enhance the competitive environment throughout the forecasting period. Some of these stakeholders are Integra Life Sciences Holding Corporation, Medtronic Plc., DePuy Synthes, B. Braun Melsungen AG, BeckerSmith Medical, Inc., and Spiegelberg GmbH and Co.KG. The mushrooming number of mergers and acquisitions and the increasing investments in research and development activities are predicted…

WednesdayJul 08, 2020 9:30 am

How Can the Diagnosis and Treatment of Rare Diseases Be Improved?

Rare diseases have brought a more significant impact on the lives of several people more than AIDS and cancer combined, and statistics show that more than 450 million people are suffering from rare diseases worldwide. These rare diseases have escalated due to lack of education, shortage of improved technologies and infrastructure, which has made the diagnosis of these diseases so challenging. However, the good news is that steps are being taken to improve the diagnosis and treatment of rare diseases worldwide. The Focus Should Be Changed from North America and Europe to the World For the last 25 years since…

TuesdayJul 07, 2020 3:30 pm

UK Company Secures Funds to Detect Epigenetic Cancer Signs

A University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Sciences Innovation. It is a local early-stage investment enterprise connected to the University of Oxford. Base Genomics will make use of technology developed at the University of Oxford called TAPS. TAPS is responsible for detecting epigenetic methylation of DNA at a single-base level. DNA methylation is a method in which cells can switch off specific genes…